Alterations in T and B cell function persist in convalescent COVID-19 patients.
B cells
COVID-19
T cells
convalescent patients
long COVID
viral Infection
Journal
Med (New York, N.Y.)
ISSN: 2666-6340
Titre abrégé: Med
Pays: United States
ID NLM: 101769215
Informations de publication
Date de publication:
11 06 2021
11 06 2021
Historique:
received:
15
10
2020
revised:
01
03
2021
accepted:
19
03
2021
pubmed:
7
4
2021
medline:
7
4
2021
entrez:
6
4
2021
Statut:
ppublish
Résumé
Emerging studies indicate that some coronavirus disease 2019 (COVID-19) patients suffer from persistent symptoms, including breathlessness and chronic fatigue; however, the long-term immune response in these patients presently remains ill-defined. Here, we describe the phenotypic and functional characteristics of B and T cells in hospitalized COVID-19 patients during acute disease and at 3-6 months of convalescence. We report that the alterations in B cell subsets observed in acute COVID-19 patients were largely recovered in convalescent patients. In contrast, T cells from convalescent patients displayed continued alterations with persistence of a cytotoxic program evident in CD8 Our data detail lymphocyte alterations in previously hospitalized COVID-19 patients up to 6 months following hospital discharge and identify 3 subgroups of convalescent patients based on distinct lymphocyte phenotypes, with 1 subgroup associated with poorer clinical outcome. We propose that alterations in B and T cell function following hospitalization with COVID-19 could affect longer-term immunity and contribute to some persistent symptoms observed in convalescent COVID-19 patients. Provided by UKRI, Lister Institute of Preventative Medicine, the Wellcome Trust, The Kennedy Trust for Rheumatology Research, and 3M Global Giving.
Sections du résumé
BACKGROUND
Emerging studies indicate that some coronavirus disease 2019 (COVID-19) patients suffer from persistent symptoms, including breathlessness and chronic fatigue; however, the long-term immune response in these patients presently remains ill-defined.
METHODS
Here, we describe the phenotypic and functional characteristics of B and T cells in hospitalized COVID-19 patients during acute disease and at 3-6 months of convalescence.
FINDINGS
We report that the alterations in B cell subsets observed in acute COVID-19 patients were largely recovered in convalescent patients. In contrast, T cells from convalescent patients displayed continued alterations with persistence of a cytotoxic program evident in CD8
CONCLUSIONS
Our data detail lymphocyte alterations in previously hospitalized COVID-19 patients up to 6 months following hospital discharge and identify 3 subgroups of convalescent patients based on distinct lymphocyte phenotypes, with 1 subgroup associated with poorer clinical outcome. We propose that alterations in B and T cell function following hospitalization with COVID-19 could affect longer-term immunity and contribute to some persistent symptoms observed in convalescent COVID-19 patients.
FUNDING
Provided by UKRI, Lister Institute of Preventative Medicine, the Wellcome Trust, The Kennedy Trust for Rheumatology Research, and 3M Global Giving.
Identifiants
pubmed: 33821250
doi: 10.1016/j.medj.2021.03.013
pii: S2666-6340(21)00115-X
pmc: PMC8011689
doi:
Substances chimiques
Cytokines
0
Interleukin-6
0
Interleukin-10
130068-27-8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
720-735.e4Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Versus Arthritis
ID : 21927
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L011840/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/V028448/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/M025977/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/S01103X/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 202865/Z/16/Z
Pays : United Kingdom
Investigateurs
Rohan Ahmed
(R)
Miriam Avery
(M)
Katharine Birchall
(K)
Evelyn Charsley
(E)
Alistair Chenery
(A)
Christine Chew
(C)
Richard Clark
(R)
Emma Connolly
(E)
Karen Connolly
(K)
Simon Dawson
(S)
Laura Durrans
(L)
Hannah Durrington
(H)
Jasmine Egan
(J)
Kara Filbey
(K)
Claire Fox
(C)
Helen Francis
(H)
Miriam Franklin
(M)
Susannah Glasgow
(S)
Nicola Godfrey
(N)
Kathryn J Gray
(KJ)
Seamus Grundy
(S)
Jacinta Guerin
(J)
Pamela Hackney
(P)
Chantelle Hayes
(C)
Emma Hardy
(E)
Jade Harris
(J)
Anu John
(A)
Bethany Jolly
(B)
Verena Kästele
(V)
Gina Kerry
(G)
Sylvia Lui
(S)
Lijing Lin
(L)
Alex G Mathioudakis
(AG)
Joanne Mitchell
(J)
Clare Moizer
(C)
Katrina Moore
(K)
Stuart Moss
(S)
Syed Murtuza Baker
(SM)
Rob Oliver
(R)
Grace Padden
(G)
Christina Parkinson
(C)
Michael Phuycharoen
(M)
Ananya Saha
(A)
Barbora Salcman
(B)
Nicholas A Scott
(NA)
Seema Sharma
(S)
Jane Shaw
(J)
Joanne Shaw
(J)
Elizabeth Shepley
(E)
Lara Smith
(L)
Simon Stephan
(S)
Ruth Stephens
(R)
Gael Tavernier
(G)
Rhys Tudge
(R)
Louis Wareing
(L)
Roanna Warren
(R)
Thomas Williams
(T)
Lisa Willmore
(L)
Mehwish Younas
(M)
Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
J Virol. 2007 Aug;81(16):8439-50
pubmed: 17553894
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Nat Rev Immunol. 2020 Sep;20(9):529-536
pubmed: 32728222
Nat Rev Immunol. 2020 Oct;20(10):590
pubmed: 32782353
Nat Med. 2020 Oct;26(10):1623-1635
pubmed: 32807934
J Infect Dis. 2018 Jan 4;217(2):245-256
pubmed: 29112724
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nature. 2020 Aug;584(7821):463-469
pubmed: 32717743
Med (N Y). 2021 Mar 12;2(3):313-320.e4
pubmed: 33554155
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
BMJ. 2020 Aug 3;370:m3001
pubmed: 32747332
Eur Respir J. 2020 Aug 27;56(2):
pubmed: 32398307
BMJ. 2020 Aug 11;370:m3026
pubmed: 32784198
Front Immunol. 2015 Jun 08;6:296
pubmed: 26106395
Lancet Microbe. 2020 Jun;1(2):e63
pubmed: 32835332
Nat Med. 2020 Apr;26(4):453-455
pubmed: 32284614
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
BMJ. 2020 Jul 30;370:m2922
pubmed: 32732337
J Clin Invest. 2017 Mar 1;127(3):772-779
pubmed: 28248202
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Nat Commun. 2020 Jul 6;11(1):3434
pubmed: 32632085
Sci Immunol. 2020 Sep 17;5(51):
pubmed: 32943497
J Dermatol Sci. 2019 Jan;93(1):2-7
pubmed: 30514664
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Arthritis Res Ther. 2005;7(5):R1001-13
pubmed: 16207316
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Immunity. 2010 Jan 29;32(1):129-40
pubmed: 20079667
Cell Mol Immunol. 2020 Jul;17(7):773-775
pubmed: 32467617
Cell. 2021 Jan 7;184(1):169-183.e17
pubmed: 33296701
Nucleic Acids Res. 2015 Jul 1;43(W1):W566-70
pubmed: 25969447
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Nat Commun. 2020 Jul 24;11(1):3730
pubmed: 32709840
Nat Med. 2020 Jul;26(7):1070-1076
pubmed: 32514174
Sci Immunol. 2020 Jul 15;5(49):
pubmed: 32669287
Cell Rep Med. 2020 Sep 22;1(6):100081
pubmed: 32839763
Sci Transl Med. 2013 Feb 20;5(173):173ra23
pubmed: 23427243
Cell Mol Immunol. 2020 May;17(5):541-543
pubmed: 32203186
Nat Immunol. 2020 Nov;21(11):1336-1345
pubmed: 32887977
Immunity. 2020 Jun 16;52(6):971-977.e3
pubmed: 32413330